Merck Patent Gmbh

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Sven Andrecht

Wilson Moya

Romas Skudas

Robertus Hendriks

Norbert Fusenig

Peter Angel

Marina Schorpp-Kistner

Klaus Adrian

Bianca Edelmann

Axel Szabowski

Nicole Maas-Szabowski

Jonas Anders

Achim Schwämmle

Anette Boerner

Bianca Edlemann

Cora Rueter

Andrea Kolbus

The present invention relates to the purification of target molecules like recombinant and/or biotherapeutic proteins. Activated carbon can be used to remove leachables and/or extractables resulting from disposable equipment employed in the process.

Activated carbon for the removal of leachables and/or extractables

The invention relates to a method and a kit for the isolation of phosphorylated peptides from complex mixtures using support materials having chelate ligands based on silica and alkaline elution buffers. In preferred embodiments, the method according to the invention enables the isolation of phosphopeptides from complex sample solutions with a reproducibly high yield and at the same time with high purity and it allows efficient ionisation and detection of the isolated phosphopeptides both by MALDI-TOF and also by ESI mass spectrometry without additional requisite method steps, such as, for example, chromatographic desalination of the sample.

Method and kit for the isolation of phosphorylated peptides

The invention relates to genetically modified fibroblast cells which comprise the following properties: (a) a gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor of the signal transduction pathway is modified resulting in a modified AP-1 activity; (b) functionally linked with a promoter, it contains in an expression vector the gene from (a) in a form such that the active subunit is only expressed after induction of the promoter or the subunit encoded by the gene is present in inactive form and a form that can be activated. Furthermore, the invention relates to a method which uses the fibroblast cell according to the invention to identify a compound which can support, inhibit or modify the AP-1-dependent differentiation and/or proliferation of keratinocytes or a gene which is involved in the AP-1-dependent differentiation and/or proliferation of keratinocytes as well as to the use of the test compound identified according to the method of the invention and the gene for treating or diagnosing diseases associated with a disturbed proliferation and/or differentiation of keratinocytes.

Genetically modified fibroblast cells

Growing community of inventors

Darmstadt, Germany

Sven Andrecht